ABUS Quote, Financials, Valuation and Earnings

Moderna, Inc. has a net margin of -1463.52% compared to Arbutus Biopharma Corp.'s net margin of -19.69%. Arbutus Biopharma Corp.'s return on equity of -47.63% beat Moderna, Inc.'s return on equity of -30.18%.

Arbutus Biopharma Corp. has a consensus price target of $5.70, signalling upside risk potential of 37.6%. On the other hand Moderna, Inc. has an analysts' consensus of $37.70 which suggests that it could fall by -16.78%. Given that Arbutus Biopharma Corp. has higher upside potential than Moderna, Inc., analysts believe Arbutus Biopharma Corp. is more attractive than Moderna, Inc..

Arbutus Biopharma Corp. has a beta of 0.703, which suggesting that the stock is 29.701% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.991%.

Arbutus Biopharma Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arbutus Biopharma Corp. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Arbutus Biopharma Corp. quarterly revenues are $529K, which are smaller than Moderna, Inc. quarterly revenues of $1B. Arbutus Biopharma Corp.'s net income of -$7.7M is higher than Moderna, Inc.'s net income of -$200M. Notably, Arbutus Biopharma Corp.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arbutus Biopharma Corp. is 54.20x versus 7.86x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -1463.52% compared to Arbutus Biopharma Corp.'s net margin of -255.85%. Arbutus Biopharma Corp.'s return on equity of -47.63% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Arbutus Biopharma Corp. has a consensus price target of $5.70, signalling upside risk potential of 37.6%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -57.5%. Given that Arbutus Biopharma Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Arbutus Biopharma Corp. is more attractive than NovaBay Pharmaceuticals, Inc..

Arbutus Biopharma Corp. has a beta of 0.703, which suggesting that the stock is 29.701% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Arbutus Biopharma Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Arbutus Biopharma Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Arbutus Biopharma Corp. quarterly revenues are $529K, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Arbutus Biopharma Corp.'s net income of -$7.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Arbutus Biopharma Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 3.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arbutus Biopharma Corp. is 54.20x versus 3.89x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -1463.52% compared to Arbutus Biopharma Corp.'s net margin of --. Arbutus Biopharma Corp.'s return on equity of -47.63% beat Palatin Technologies's return on equity of --.

Arbutus Biopharma Corp. has a consensus price target of $5.70, signalling upside risk potential of 37.6%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Arbutus Biopharma Corp., analysts believe Palatin Technologies is more attractive than Arbutus Biopharma Corp..

Arbutus Biopharma Corp. has a beta of 0.703, which suggesting that the stock is 29.701% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Arbutus Biopharma Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arbutus Biopharma Corp. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Arbutus Biopharma Corp. quarterly revenues are $529K, which are larger than Palatin Technologies quarterly revenues of --. Arbutus Biopharma Corp.'s net income of -$7.7M is higher than Palatin Technologies's net income of --. Notably, Arbutus Biopharma Corp.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arbutus Biopharma Corp. is 54.20x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Trevi Therapeutics, Inc. has a net margin of -1463.52% compared to Arbutus Biopharma Corp.'s net margin of --. Arbutus Biopharma Corp.'s return on equity of -47.63% beat Trevi Therapeutics, Inc.'s return on equity of -35.48%.

Arbutus Biopharma Corp. has a consensus price target of $5.70, signalling upside risk potential of 37.6%. On the other hand Trevi Therapeutics, Inc. has an analysts' consensus of $21.30 which suggests that it could grow by 102.66%. Given that Trevi Therapeutics, Inc. has higher upside potential than Arbutus Biopharma Corp., analysts believe Trevi Therapeutics, Inc. is more attractive than Arbutus Biopharma Corp..

Arbutus Biopharma Corp. has a beta of 0.703, which suggesting that the stock is 29.701% less volatile than S&P 500. In comparison Trevi Therapeutics, Inc. has a beta of 0.907, suggesting its less volatile than the S&P 500 by 9.324%.

Arbutus Biopharma Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trevi Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arbutus Biopharma Corp. pays -- of its earnings as a dividend. Trevi Therapeutics, Inc. pays out -- of its earnings as a dividend.

Arbutus Biopharma Corp. quarterly revenues are $529K, which are larger than Trevi Therapeutics, Inc. quarterly revenues of --. Arbutus Biopharma Corp.'s net income of -$7.7M is higher than Trevi Therapeutics, Inc.'s net income of -$11.8M. Notably, Arbutus Biopharma Corp.'s price-to-earnings ratio is -- while Trevi Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arbutus Biopharma Corp. is 54.20x versus -- for Trevi Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.